New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration. 2002

Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, Kyoto Pharmaceutical University, Yamashina-Ku, Kyoto, Japan.

To improve the low water-solubility of HIV protease inhibitors, we synthesized water-soluble prodrugs of KNI-272 and KNI-279 which are potent HIV-1 protease inhibitors consisting of an Apns-Thz core structure (Apns; allophenylnorstatine, Thz; thiazolidine-4-carboxylic acid) as an inhibitory machinery. The prodrugs, which contained an O-acyl peptidomimetic structure with an ionized amino group leading to the increase of water-solubility, were designed to regenerate the corresponding parent drugs based on the O-->N intramolecular acyl migration reaction at the alpha-hydroxy-beta-amino acid residue, that is allophenylnorstatine. The synthetic prodrugs 3, 4, 6, and 7 improved the water-solubility (>300mg/mL) more than 4000-fold in comparison with the parent compounds, which is the practically acceptable value as water-soluble drugs. These prodrugs were stable as an HCl salt and in a strongly acidic solution corresponding to gastric juice (pH 2.0), and could be converted to the parent compounds promptly in the aqueous condition from slightly acidic to basic pH at 37 degrees C, with the suitable migration rate, via a five-membered ring intermediate. Using a similar method, we synthesized a prodrug (12) of ritonavir, a clinically useful HIV-1 protease inhibitor as an anti-AIDS drug. In contrast to the prodrugs 3, 4, 6, and 7, the prodrug 12 was very slowly converted to ritonavir probably through a six-membered ring intermediate, with the t(1/2) value of 32h that may not be suitable for practical use.

UI MeSH Term Description Entries
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000215 Acylation The addition of an organic acid radical into a molecule.
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
January 2004, Bioorganic & medicinal chemistry,
Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
December 2003, Bioorganic & medicinal chemistry letters,
Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
August 2003, Bioorganic & medicinal chemistry letters,
Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
April 2005, Journal of medicinal chemistry,
Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
February 2001, Bioorganic & medicinal chemistry letters,
Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
January 2003, Current pharmaceutical design,
Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
January 2012, Journal of Asian natural products research,
Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
January 2004, Biopolymers,
Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
January 2007, Current medicinal chemistry,
Yoshio Hamada, and Jun Ohtake, and Youhei Sohma, and Tooru Kimura, and Yoshio Hayashi, and Yoshiaki Kiso
August 2003, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!